Article

Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical Exposures

2025-11-03

Abstract excerpt

<h4>ABSTRACT</h4> Somatic missense mutations in oncogenes drive resistance to anticancer drugs, yet many variants remain clinically uncharacterized. Analogous to Variants of Uncertain Significance (VUS) in genetic disorders, these Variants of Uncertain Drug Resistance (VUDRs) in cancer lack the functional annotation needed to guide clinical management. Here, we applied a standards-driven deep mutational scanning...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f8f4a8d9-c26a-51ea-aa88-33f536a8519b
DOI: 10.1101/2025.10.31.685392

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical ExposuresDOI 10.1101/2025.10.31.685392Read

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read

Genetic variation in human drug-related genesSemantic proximity Read

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and OpportunitiesSemantic proximity Read

Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3D.Semantic proximity Read

Genomic landscape of drug binding and pharmacogenetic variation across diverse populations using SNPdrug3DSemantic proximity Read

PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network.Semantic proximity Read

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read

High-throughput assays to assess variant effects on disease.Semantic proximity Read

Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2Semantic proximity Read

Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.Semantic proximity Read

The impact of germline mutations on targeted therapy.Semantic proximity Read

Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editingSemantic proximity Read